Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.61 USD
+0.07 (2.76%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.61 USD
+0.07 (2.76%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Zacks News
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics (PSTX) delivered earnings and revenue surprises of 25.58% and 88.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
by Zacks Equity Research
Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -16.67% and 23.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adaptimmune (ADAP) Down on End of Collaboration With Roche
by Zacks Equity Research
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 25% and 99.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 3.64% and 1.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -12.50% and 3.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?